Journal of Bone and Mineral Metabolism最新文献

{"title":"Trends in the incidence of secondary hip fractures and osteoporosis treatment in Japan (FY2012-FY2023).","authors":"Shinichi Nakatoh, Kenji Fujimori, Shigeyuki Ishii, Junko Tamaki, Nobukazu Okimoto, Sumito Ogawa, Masayuki Iki","doi":"10.1007/s00774-026-01695-2","DOIUrl":"10.1007/s00774-026-01695-2","url":null,"abstract":"<p><strong>Introduction: </strong>This study aimed to clarify trends in the incidence of secondary hip fractures and pharmacotherapy after primary fractures over time in Japan.</p><p><strong>Materials and methods: </strong>Using Japan's National Database of Health Insurance Claims and Specific Health Checkups, we examined the number of hip fracture patients and their osteoporosis medication status from fiscal year (FY) 2012 to FY2023.</p><p><strong>Results: </strong>A total of 1,289,333 females and 312,968 males had primary fractures. Among them, 42,835 females and 8,249 males had a secondary fracture within 1 year following the primary fracture. The incidence rates averaged 3.44% annually, ranging from 3.26 to 3.57% by fiscal year. These rates showed an increasing trend from FY2012 to FY2018, followed by a decreasing trend until FY2020, but increased again in FY2021. The medication administration rate within the first year following the primary fracture progressively increased over time, from 39.1% in FY2012 to 49.6% in FY2021, followed by a notable increase to 65.5% in FY2022. Bisphosphonates were the most frequently administered medications, and the number of patients receiving bisphosphonates, eldecalcitol, denosumab, and romosozumab increased over time.</p><p><strong>Conclusion: </strong>The medication administration rate has consistently increased. The incidence of secondary fractures decreased from FY2019 but then increased in FY2021 due to the impact of the coronavirus disease 2019 (COVID-19) pandemic. However, in FY2022, this increase was mitigated by the introduction of management fees. It is anticipated that the incidence of secondary fractures will decline again due to a further increase in medication rates following the COVID-19 pandemic.</p>","PeriodicalId":15116,"journal":{"name":"Journal of Bone and Mineral Metabolism","volume":" ","pages":"386-395"},"PeriodicalIF":2.9,"publicationDate":"2026-05-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"146165310","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Bone fragility and atypical femoral fractures in SLE: role of disease activity, infection, and treatment.","authors":"Hiroe Sato, Naoki Kondo, Tomoya Watarai, Eriko Hasegawa, Ayako Wakamatsu, Yukiko Nozawa, Daisuke Kobayashi, Takeshi Kuroda, Suguru Yamamoto","doi":"10.1007/s00774-025-01683-y","DOIUrl":"10.1007/s00774-025-01683-y","url":null,"abstract":"<p><strong>Introduction: </strong>To determine the incidence and risk factors of fragility fractures and atypical femoral fracture (AFF)-related events in patients with systemic lupus erythematosus (SLE) receiving long-term glucocorticoid (GC) therapy.</p><p><strong>Materials and methods: </strong>A retrospective analysis was conducted of 170 SLE patients followed from 2016 to 2023. Data on GC use, bisphosphonate (BP) therapy, bone-related events, and clinical characteristics were collected. Risk factors for fragility fractures and AFF-related events, including localized periosteal thickening (LPT), were analyzed using multivariate logistic regression.</p><p><strong>Results: </strong>Although the median daily dose of prednisolone decreased over time, 82.9% of patients still met the criteria for pharmacologic intervention for GC-induced osteoporosis in 2023, and most continued to receive > 5 mg/day of GC. The median duration of BP therapy was 10.4 years, with 69 patients maintaining BP treatment throughout the observation period (median, 12.5 years). Fragility fractures and AFF-related events occurred in 7.6% and 5.8% of patients, respectively. Fragility fractures were independently associated with SLE flares and infection-related hospitalizations, whereas AFF-related events were significantly associated with prolonged BP use.</p><p><strong>Conclusion: </strong>Despite a gradual reduction in GC dosage, many patients with longstanding SLE remain at elevated risk for fractures. The comparable frequencies of fragility fractures and AFF-related events highlight the clinical relevance of both complications. The prevention of SLE flares and infections may contribute to lowering the risk of fragility fractures. In addition, careful monitoring for AFF/LPT is warranted in patients receiving long-term BP and GC therapy.</p>","PeriodicalId":15116,"journal":{"name":"Journal of Bone and Mineral Metabolism","volume":" ","pages":"336-345"},"PeriodicalIF":2.9,"publicationDate":"2026-05-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145892551","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Lactate and lactylation in osteoporosis: pathogenesis, regulation, and future perspectives.","authors":"Jianhao Sun, Miao Ge, Peng Gao, Nan Zhang, Tingting Huang, Tao Liu","doi":"10.1007/s00774-026-01722-2","DOIUrl":"10.1007/s00774-026-01722-2","url":null,"abstract":"<p><p>Osteoporosis is a metabolic bone disease characterized by bone microstructural degeneration and increased fracture risk, primarily driven by an imbalance in bone homeostasis. Recent studies have revealed that lactate metabolic remodeling and its derived lactylation modifications play a pivotal role in the dynamic balance between bone formation and resorption by regulating the metabolic-epigenetic network within the bone microenvironment. This review systematically examines the role of lactate metabolic pathways in the energy reprogramming of osteoblasts, analyzes the molecular mechanisms of lactylation in osteogenesis-osteoclastogenesis coupling, and discusses the challenges and future directions of novel therapeutic strategies targeting the lactate metabolism axis. By elucidating the critical role of lactate metabolism in the pathogenesis of osteoporosis, this review aims to enhance comprehensive understanding and facilitate the development of effective therapeutic interventions.</p>","PeriodicalId":15116,"journal":{"name":"Journal of Bone and Mineral Metabolism","volume":" ","pages":"277-287"},"PeriodicalIF":2.9,"publicationDate":"2026-05-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147639063","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Critical appraisal of \"Preoperative treatment and postoperative outcomes in osteoporotic patients with vertebral fractures: a longitudinal database study\".","authors":"Mihir Manuja","doi":"10.1007/s00774-025-01665-0","DOIUrl":"10.1007/s00774-025-01665-0","url":null,"abstract":"","PeriodicalId":15116,"journal":{"name":"Journal of Bone and Mineral Metabolism","volume":" ","pages":"442-443"},"PeriodicalIF":2.9,"publicationDate":"2026-05-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145603962","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Inverse association between diet quality and the risk of osteoporotic fractures: a cross-sectional analysis.","authors":"Xi Liu, Bin Xu","doi":"10.1007/s00774-026-01705-3","DOIUrl":"10.1007/s00774-026-01705-3","url":null,"abstract":"<p><strong>Introduction: </strong>This study aimed to systematically evaluate the association between the Healthy Eating Index (HEI-2020), the Alternative Healthy Eating Index (AHEI), and the risk of osteoporotic fractures based on the National Health and Nutrition Examination Survey (NHANES) database.</p><p><strong>Materials and methods: </strong>We included 13,541 participants from NHANES data, of whom 1,646 experienced osteoporotic fractures. Diet quality was assessed using HEI-2020 and AHEI scores. Weighted multivariable logistic regression, restricted cubic spline (RCS) analysis, and subgroup analyses were applied to evaluate the relationship between HEI-2020, AHEI, and osteoporotic fracture risk.</p><p><strong>Results: </strong>After full adjustment for confounding factors, each 1-point increase in HEI-2020 and AHEI scores was associated with a 1.5% (OR = 0.985, 95% CI: 0.978-0.992) and 1.3% (OR = 0.987, 95% CI: 0.980-0.994) reduction in osteoporotic fracture risk, respectively. RCS analysis indicated that both HEI-2020 (p for nonlinear = 0.2911) and AHEI (p for nonlinear = 0.3951) were linearly and inversely associated with osteoporotic fracture risk (all P overall < 0.0001). Subgroup analyses showed that this association remained consistent across populations stratified by sex, age, BMI, smoking status, hypertension, diabetes, and cardiovascular disease, with no significant interactions observed. Sensitivity analyses excluding participants who reported the use of prescription medications for hypertension or diabetes yielded results consistent with the primary analyses after multivariable adjustment.</p><p><strong>Conclusion: </strong>This study systematically showed a significant inverse association between HEI-2020, AHEI, and osteoporotic fracture risk. The findings suggest that improving diet quality may be a feasible strategy for preventing osteoporotic fractures, with broad population applicability and public health implications.</p>","PeriodicalId":15116,"journal":{"name":"Journal of Bone and Mineral Metabolism","volume":" ","pages":"418-428"},"PeriodicalIF":2.9,"publicationDate":"2026-05-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147443809","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Comment on \"One‑year bone mineral density gains with anti‑osteoporotic medications and clinical factors associated with non‑BMD gainers\".","authors":"Jie Xiao, XiaoTian Li, Jiaqi Huang","doi":"10.1007/s00774-025-01674-z","DOIUrl":"10.1007/s00774-025-01674-z","url":null,"abstract":"","PeriodicalId":15116,"journal":{"name":"Journal of Bone and Mineral Metabolism","volume":" ","pages":"450-451"},"PeriodicalIF":2.9,"publicationDate":"2026-05-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145892605","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Response to letter to the editor on \"Preoperative treatment and postoperative outcomes in osteoporotic patients with vertebral fractures: a longitudinal database study\".","authors":"Ruriko Koto, Shiori Yoshida, Akihiro Nakajima, Tetsuya Miwa, Naohisa Miyakoshi","doi":"10.1007/s00774-025-01679-8","DOIUrl":"10.1007/s00774-025-01679-8","url":null,"abstract":"","PeriodicalId":15116,"journal":{"name":"Journal of Bone and Mineral Metabolism","volume":" ","pages":"444-445"},"PeriodicalIF":2.9,"publicationDate":"2026-05-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145849929","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Osteoporosis risk with sodium-glucose cotransporter 2 inhibitors versus thiazolidinediones in older women with diabetes.","authors":"Hyeon Jeong Lee, Pusoon Chun","doi":"10.1007/s00774-026-01696-1","DOIUrl":"10.1007/s00774-026-01696-1","url":null,"abstract":"<p><strong>Introduction: </strong>This study aimed to compare the risk of osteoporosis between sodium-glucose cotransporter 2 inhibitors (SGLT2is) and thiazolidinediones (TZDs) in older women with type 2 diabetes (T2D).</p><p><strong>Materials and methods: </strong>We conducted a population-based cohort study using the Korean National Health Insurance data. This study included women aged ≥ 55 years with T2D who used SGLT2is or TZDs between January 2022 and December 2023. Inverse probability of treatment weighting (IPTW) using propensity scores was employed to balance baseline covariates between SGLT2i and TZD users. Adjusted hazard ratios (aHRs) were estimated using multivariable weighted Cox proportional hazards models.</p><p><strong>Results: </strong>Among 8,304 and 2,147 patients who initiated SGLT2i or TZD therapy, respectively, 5,358 SGLT2i and 1,169 TZD users were included in the Cox model. SGLT2i use was associated with a lower risk of osteoporosis than TZD use (aHR, 0.78; 95% confidence interval [CI] 0.69-0.89). The incidence rates of osteoporosis were 6.7 (95% CI 6.0-7.4) and 9.1 (95% CI 7.4-10.9) per 100 person-years for SGLT2i and TZD users, respectively. Compared with non-use, use of proton pump inhibitors (PPIs) for 270-364 days and metformin in the year prior to follow-up were associated with higher osteoporosis risk (aHRs 1.25 [95% CI 1.01-1.55] and 1.31 [95% CI 1.10-1.55], respectively).</p><p><strong>Conclusion: </strong>Despite concerns about a potential association between SGLT2is and reduced bone mineral density, our findings suggest a lower risk of osteoporosis with SGLT2is than with TZDs among older, likely postmenopausal women with T2D.</p>","PeriodicalId":15116,"journal":{"name":"Journal of Bone and Mineral Metabolism","volume":" ","pages":"375-385"},"PeriodicalIF":2.9,"publicationDate":"2026-05-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"146219804","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Association of serum magnesium levels and calcimimetic use: fractures and cardiovascular events in Japanese haemodialysis patients.","authors":"Tomohiro Saito, Masahide Mizobuchi, Kiryu Yoshida, Tadashi Kato, Kazuki Abe, Toshiaki Takezaki, Noriyuki Kato, Eisuke Inoue, Hiroaki Ogata, Fumihiko Koiwa, Hirokazu Honda","doi":"10.1007/s00774-025-01682-z","DOIUrl":"10.1007/s00774-025-01682-z","url":null,"abstract":"<p><strong>Introduction: </strong>Though low serum magnesium (Mg) levels are associated with adverse outcomes in patients on haemodialysis, the interaction with calcimimetics remains uncertain. We hypothesized a potential interaction between serum Mg levels and calcimimetic use in cardiovascular events (CVEs), all-cause mortality, and new fractures during follow-up in patients on haemodialysis.</p><p><strong>Materials and methods: </strong>This single-centre retrospective cohort included 399 Japanese adults on maintenance haemodialysis, followed for ≤ 5 years. Cox models with time-dependent serum Mg levels and calcimimetic usage interaction adjusted for clinicodemographic and biochemical covariates.</p><p><strong>Results: </strong>At baseline, 205 patients (51.4%) were prescribed calcimimetics (median serum Mg, 2.5 mg/dL). The mean observational period was 40.6 months, and 122 CVEs, 159 all-cause mortality, and 69 new fractures occurred (incidence rates: 0.09, 0.10-, and 0.05 per patient-year), respectively. The time-dependent model showed serum Mg < 2.4 mg/dL was associated with a markedly higher risk for new fractures in calcimimetic-naïve patients. Serum Mg levels were not significantly associated with CVEs and all-cause mortality, regardless of calcimimetic usage. The restricted cubic spline curve demonstrated linear inverse trends of serum Mg levels with all-cause mortality and new fractures in calcimimetic-naïve patients. However, no significant interaction between Mg and calcimimetic use was observed for any outcome.</p><p><strong>Conclusion: </strong>We did not detect a statistically significant interaction between serum Mg levels and calcimimetic use. Nonetheless, low serum Mg (< 2.4 mg/dL) was associated with a higher risk of fractures, particularly among calcimimetic-naïve patients. Thus, low serum Mg is a potentially modifiable risk marker associated with fracture risk, particularly in calcimimetic-naïve patients.</p>","PeriodicalId":15116,"journal":{"name":"Journal of Bone and Mineral Metabolism","volume":" ","pages":"312-324"},"PeriodicalIF":2.9,"publicationDate":"2026-05-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"146100020","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Causal association between gut microbiota and osteonecrosis in European populations: a two-sample Mendelian randomization analysis.","authors":"Haiqing Li, Zhen Yang, Mingfeng Li, Huiqin Yang, Dejiu Liu, Yuke Bi, Xuejun Dai, Xin Chen, Lirong Miao, Fang Yang, Zhuoyuan Chen","doi":"10.1007/s00774-026-01704-4","DOIUrl":"10.1007/s00774-026-01704-4","url":null,"abstract":"<p><strong>Introduction: </strong>Recent studies have linked gut microbiota composition to osteonecrosis, but the causal relationship remains unclear. Clarifying this relationship is clinically important because osteonecrosis currently lacks early biomarkers and etiology-targeted therapies; if causal, the gut microbiome would offer a readily modifiable intervention target.</p><p><strong>Methods: </strong>We conducted a two-sample Mendelian randomization analysis to explore this relationship. Exposure data were sourced from the MiBioGen consortium (N = 18,340), while outcome data on osteonecrosis were obtained from FinnGen (N = 392,580). The Inverse Variance Weighted method was used as the primary analytical approach, supplemented by comprehensive sensitivity analyses to assess the robustness of our findings.</p><p><strong>Results: </strong>Our analysis screened 196 microbial taxa and identified seven taxa associated with osteonecrosis risk in European populations. Protective effects were noted for the genus Odoribacter (OR = 0.579; P = 0.027) and family Alcaligenaceae (OR = 0.703; P = 0.049). Conversely, increased risk was linked to the genus Eubacterium fissicatena group (OR = 1.272; P = 0.046), genus Bifidobacterium (OR = 1.372; P = 0.038), order Bifidobacteriales (OR = 1.412; P = 0.023), family Bifidobacteriaceae (OR = 1.412; P = 0.023) and phylum Actinobacteria (OR = 1.750; P = 0.001). Sensitivity analyses confirmed the robustness of these findings, with no evidence of pleiotropy or heterogeneity.</p><p><strong>Conclusion: </strong>This study establishes a causal link between gut microbiota composition and osteonecrosis, suggesting that gut microbiota may be a modifiable factor in its pathogenesis. Further research is needed to elucidate underlying mechanisms and evaluate microbiota-targeted interventions for prevention and treatment.</p>","PeriodicalId":15116,"journal":{"name":"Journal of Bone and Mineral Metabolism","volume":" ","pages":"406-417"},"PeriodicalIF":2.9,"publicationDate":"2026-05-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"146213248","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}